Lundbeck still looking for acquisitions despite positive Alzheimer's data

Pharmaceutical firm Lundbeck is still considering acquisition opportunities even though it is heading to the approval application stage for its Alzheimer’s medication.

Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH

Lundbeck is still interested in acquisitions, despite the fact that the firm and its partner Otsuka Pharmaceuticals released positive phase III data for its candidate brexpiprazol on Monday. The target indication is agitation in Alzheimer’s patients, which is often demonstrated through angry outbursts.

”We know that we need to address Lundbeck’s future growth, in terms of the next five to ten years” CEO Deborah Dunsire tells Danish financial daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs